• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清睾酮未被认识的动力学:对前列腺癌短期雄激素剥夺治疗的影响。

Unrecognized kinetics of serum testosterone: impact on short-term androgen deprivation therapy for prostate cancer.

作者信息

Koo Kyo Chul, Lee Dong Hoon, Kim Kyu Hyun, Lee Seung Hwan, Hong Chang Hee, Hong Sung Joon, Chung Byung Ha

机构信息

Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. ; Sex Offender Treatment and Rehabilitation Center, National Forensic Hospital, Gongju, Korea.

Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea.

出版信息

Yonsei Med J. 2014 May;55(3):570-5. doi: 10.3349/ymj.2014.55.3.570. Epub 2014 Apr 1.

DOI:10.3349/ymj.2014.55.3.570
PMID:24719121
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3990065/
Abstract

PURPOSE

To evaluate the kinetics of serum testosterone (T) recovery following short-term androgen deprivation therapy (ADT), as the understanding thereof is essential for the proper management of prostate cancer (PCa), especially intermittent ADT.

MATERIALS AND METHODS

This prospective analysis included male sex offenders who voluntarily received leuprolide acetate in order to alleviate sexual aberrance. Thirty-three and 25 patients who received 3 and 6 months of ADT were assigned to Group A and Group B, respectively. Serum T levels were obtained every week during the on-cycle period, then monthly during the off-cycle period for at least 12 months.

RESULTS

The kinetics of serum T during the on-cycle period were similar in both groups. After flare reaction at week 2, a nadir of 0.45±0.29 ng/mL was achieved. In Group A, an abrupt rebound-upsurge was observed during the first 2 month off-cycle period, which surpassed the baseline level and reached a plateau level of 8.74±2.11 ng/mL during the flare (p<0.001). This upsurge was followed by a gradual decline back to baseline over the following 10 months. In Group B, a gradual increase was observed, and a baseline level of 7.26±1.73 ng/mL was reached at 5 months. Thereafter, an ongoing upsurge that surpassed baseline levels was observed until 12 months (8.81±1.92 ng/mL; p=0.002).

CONCLUSION

The kinetics of serum T recovery during the off-cycle period varied according to the duration of ADT. Serum T should be monitored beyond normalization, as an excessive rebound may improve quality-of-life, but hamper the treatment efficacy of PCa.

摘要

目的

评估短期雄激素剥夺治疗(ADT)后血清睾酮(T)恢复的动力学,因为了解这一点对于前列腺癌(PCa)尤其是间歇性ADT的合理管理至关重要。

材料与方法

这项前瞻性分析纳入了自愿接受醋酸亮丙瑞林以减轻性异常行为的男性性犯罪者。分别将接受3个月和6个月ADT的33例和25例患者分为A组和B组。在治疗周期内每周测定血清T水平,然后在治疗周期外每月测定至少12个月。

结果

两组在治疗周期内血清T的动力学相似。在第2周出现flare反应后,血清T最低点达到0.45±0.29 ng/mL。在A组,治疗周期外的前2个月观察到血清T突然反弹升高,超过基线水平,并在flare期间达到8.74±2.11 ng/mL的平台期水平(p<0.001)。随后在接下来的10个月中逐渐下降至基线水平。在B组,观察到血清T逐渐升高,在5个月时达到7.26±1.73 ng/mL的基线水平。此后,观察到血清T持续升高超过基线水平,直至12个月(8.81±1.92 ng/mL;p=0.002)。

结论

治疗周期外血清T恢复的动力学因ADT持续时间而异。血清T应在恢复正常后继续监测,因为过度反弹可能改善生活质量,但会妨碍PCa的治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7e3/3990065/d4dc823afa14/ymj-55-570-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7e3/3990065/f3e3b14f3092/ymj-55-570-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7e3/3990065/d4dc823afa14/ymj-55-570-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7e3/3990065/f3e3b14f3092/ymj-55-570-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7e3/3990065/d4dc823afa14/ymj-55-570-g002.jpg

相似文献

1
Unrecognized kinetics of serum testosterone: impact on short-term androgen deprivation therapy for prostate cancer.血清睾酮未被认识的动力学:对前列腺癌短期雄激素剥夺治疗的影响。
Yonsei Med J. 2014 May;55(3):570-5. doi: 10.3349/ymj.2014.55.3.570. Epub 2014 Apr 1.
2
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.非转移性前列腺癌有限雄激素剥夺治疗后血清雄激素正常化的动力学及与睾酮储备相关的因素
J Urol. 2008 Oct;180(4):1432-7; discussion 1437. doi: 10.1016/j.juro.2008.06.017. Epub 2008 Aug 16.
3
Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer.前列腺癌患者长期雄激素剥夺治疗后的激素反应恢复情况。
Scand J Urol. 2016 Dec;50(6):425-428. doi: 10.1080/21681805.2016.1227876. Epub 2016 Sep 14.
4
Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.雄激素剥夺疗法治疗前列腺癌后睾酮的恢复情况。
J Sex Med. 2019 Jun;16(6):872-879. doi: 10.1016/j.jsxm.2019.03.273. Epub 2019 May 9.
5
Effects of chemical castration on sex offenders in relation to the kinetics of serum testosterone recovery: implications for dosing schedule.化学阉割对性犯罪者的影响与血清睾酮恢复动力学的关系:对给药方案的启示
J Sex Med. 2014 May;11(5):1316-24. doi: 10.1111/jsm.12492. Epub 2014 Feb 27.
6
A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.促性腺激素释放激素(GnRH)激动剂与GnRH拮抗剂在新辅助雄激素剥夺疗法联合经会阴前列腺近距离放疗治疗局限性前列腺癌中的疗效比较研究。
BMC Cancer. 2016 Sep 1;16(1):708. doi: 10.1186/s12885-016-2737-8.
7
Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.连续与间歇性雄激素剥夺疗法治疗转移性前列腺癌。
Urol Oncol. 2013 Jul;31(5):549-56. doi: 10.1016/j.urolonc.2011.03.008. Epub 2011 May 10.
8
Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.短期黄体生成素释放激素拮抗剂作为中危前列腺癌外放射治疗新辅助治疗对患者血清睾酮水平和性功能的恢复:初步前瞻性研究。
Clin Genitourin Cancer. 2018 Apr;16(2):135-141.e1. doi: 10.1016/j.clgc.2017.09.009. Epub 2017 Sep 23.
9
Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.胰岛素样生长因子-1 与接受促性腺激素释放激素类似物进行局部前列腺癌雄激素剥夺治疗的男性黄体生成素产生的调节有关。
Urol Oncol. 2012 Sep;30(5):596-601. doi: 10.1016/j.urolonc.2010.11.001. Epub 2011 Apr 1.
10
Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.接受前列腺癌长期药物去势治疗的男性在促黄体生成素释放激素激动剂治疗停止后激素恢复的个体差异。
Scand J Urol Nephrol. 2006;40(3):198-203. doi: 10.1080/00365590600641533.

引用本文的文献

1
Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer.多西他赛与雄激素剥夺疗法联合治疗转移性去势抵抗性前列腺癌的生存结局
Yonsei Med J. 2016 Sep;57(5):1070-8. doi: 10.3349/ymj.2016.57.5.1070.
2
Pharmacological interventions for those who have sexually offended or are at risk of offending.针对有性犯罪行为或有性犯罪风险者的药物干预措施。
Cochrane Database Syst Rev. 2015 Feb 18;2015(2):CD007989. doi: 10.1002/14651858.CD007989.pub2.
3
Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer.

本文引用的文献

1
Effects of chemical castration on sex offenders in relation to the kinetics of serum testosterone recovery: implications for dosing schedule.化学阉割对性犯罪者的影响与血清睾酮恢复动力学的关系:对给药方案的启示
J Sex Med. 2014 May;11(5):1316-24. doi: 10.1111/jsm.12492. Epub 2014 Feb 27.
2
Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis.间歇性雄激素剥夺疗法与传统连续性雄激素剥夺疗法治疗晚期前列腺癌的疗效比较:一项荟萃分析。
Urology. 2013 Aug;82(2):327-33. doi: 10.1016/j.urology.2013.01.078.
3
Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
去势抵抗性前列腺癌患者在抗雄激素撤药期间前列腺特异性抗原(PSA)呈指数上升,预示着多西他赛化疗后PSA会出现激增。
Yonsei Med J. 2015 Mar;56(2):368-74. doi: 10.3349/ymj.2015.56.2.368.
前列腺癌的间歇性雄激素剥夺疗法:基于 3 期临床试验的批判性评价。
Eur Urol. 2013 Nov;64(5):722-30. doi: 10.1016/j.eururo.2013.04.020. Epub 2013 Apr 19.
4
Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.度他雄胺可降低前列腺癌风险,从而改善良性前列腺增生的预后:度他雄胺减少前列腺癌事件(REDUCE)试验的二次分析。
Urology. 2011 Sep;78(3):641-6. doi: 10.1016/j.urology.2011.03.063. Epub 2011 Jul 20.
5
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer.同谋:前列腺癌中 AR 活性和雄激素合成的去调控。
Trends Endocrinol Metab. 2010 May;21(5):315-24. doi: 10.1016/j.tem.2010.01.002. Epub 2010 Feb 6.
6
Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer.醋酸亮丙瑞林长效制剂治疗前列腺癌。
Clin Interv Aging. 2009;4:259-67. doi: 10.2147/cia.s4885. Epub 2009 Jun 9.
7
Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.间歇性雄激素抑制对睾酮恢复和骨矿物质密度的长期影响:一项33个月观察性研究的结果
BJU Int. 2009 Sep;104(6):806-12. doi: 10.1111/j.1464-410X.2009.08458.x. Epub 2009 Mar 5.
8
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.非转移性前列腺癌有限雄激素剥夺治疗后血清雄激素正常化的动力学及与睾酮储备相关的因素
J Urol. 2008 Oct;180(4):1432-7; discussion 1437. doi: 10.1016/j.juro.2008.06.017. Epub 2008 Aug 16.
9
Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.基于血清睾酮水平确定促黄体生成素释放激素激动剂的给药间隔:一项前瞻性研究。
J Urol. 2007 Jun;177(6):2132-5; discussion 2135. doi: 10.1016/j.juro.2007.01.157.
10
Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.局部晚期前列腺癌——对放疗后出现前列腺特异性抗原复发证据的男性进行间歇性雄激素抑制的前瞻性II期研究的生化结果。
Cancer. 2007 Mar 1;109(5):858-67. doi: 10.1002/cncr.22464.